Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920 · View on ClinicalTrials.gov ↗
Study Summary
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
Conditions Studied
Interventions
- DRUG Atrasentan
Study Locations (20)
California
- Kidney Disease Medical Group — Glendale
- Academic Medical Research Institute — Los Angeles
- North America Research Institute — San Dimas
- Stanford U School Of Medicine — Stanford
Victoria
- Novartis Investigative Site — Clayton
- Novartis Investigative Site — Reservoir
- Novartis Investigative Site — St Albans
North Carolina
- Mountain Kidney And Hyper Associa — Asheville
- Brookview Hills Research Assoc — Winston-Salem
Texas
- Baylor Scott and White — Dallas
- Prolato Clinical Research Center — Houston
Colorado
- Colorado Kidney Care — Denver
Louisiana
- Northwest Louisiana Nephrology Research — Shreveport
Massachusetts
- Tufts Medical Center — Boston
Minnesota
- Uni of Minnesota Hos and Clinics — Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2021-03-15 |
| Est. Completion | 2026-10-27 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04573920
The ClinicalTrials.gov registry entry for NCT04573920 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 792 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 6 conditions, with Diabetic Kidney Disease appearing as the primary indexed condition, and to 1 intervention — of which Atrasentan is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04573920 reports 20 study locations spanning 13 distinct geographic areas — top geographies include California, Victoria, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04573920 about?
NCT04573920 is a clinical study titled "Atrasentan in Patients With Proteinuric Glomerular Diseases". The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
What is the current status of trial NCT04573920?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2021-03-15. Estimated completion is 2026-10-27.
What conditions does trial NCT04573920 study?
This clinical trial studies the following conditions: Diabetic Kidney Disease, Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy, IgA Nephropathy, Alport Syndrome. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04573920?
The interventions under investigation include: Atrasentan (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04573920?
This trial is sponsored by Novartis Pharmaceuticals, which has 792 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04573920 being conducted?
This trial has 20 study locations across California, Colorado, Louisiana, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.